Ready to publish: "Roche Built a $150 DNA Sequencer. Why It Can't Touch Illumina's Clinical Turf Yet"
Rachel → approved "Roche Built a $150 DNA Sequencer. Why It Can't Touch Illumina's Clinical Turf Yet": "Approved. Strong mechanism write-up and accurate research-only framing. Watch for IVD pathway signals and independent cost benchmarks in the next 12 months."
Giskard → needsreporterrevision: The claim_ledger for finding-002 (Stratos Genomics 2020 acquisition) remains attributed to FierceBiotech, which does not support that claim. The ledger entry must be corrected to attribute to the Roche SBX platform page or another supporting source before closure.
Giskard → needsreporterrevision: "roughly two-thirds of hospital laboratories through its cobas diagnostics line" — The 'two-thirds of hospital laboratories' cobas installed-base figure appears in the draft but is not supported by any of the supplied source artifacts. The FierceBiotech launch article, Roche product page, SBX platform page, and omicsomics blog all lack this figure.
Iris → adapt: "Source is publishable and the Axelios 1 vs Illumina frame is the right spine, but the title must do more category/stakes work for non-beat readers and the lede has to land the research-only caveat early so the competitive read is not overstated. Preserve legitimate criticism: Roche explicitly positions Axelios 1 as research-use-only, so any framing that implies immediate clinical disruption of Illumina's installed base overstates what the source supports. Keep the named partnerships (Hartwig Medical Foundation, Broad Clinical Labs, 10x Genomics, Google DeepVariant, open-source XOOS) as credibility signal rather than proof of clinical traction, and flag Xpandomers as a Roche-coined term that needs a one-line definition on first use."
Curie → pursuing: "Reporter should hydrate the FierceBiotech source, retrieve Roche's own press release or launch announcement, and verify Axelrios 1's actual specs, pricing tier, and stated competitive differentiators versus Illumina's current NovaSeq or NovaSeq X workflow. The core Type0 question is whether Roche's entry represents a credible sequencing-infrastructure challenger that could unbundle Illumina's installed base in pharma/biotech research, or whether this is another entrant that will remain niche. Draft angle: 'Roche's sequencing counteroffensive: what Axelrios 1 changes or doesn't change for Illumina's dominance in drug-discovery infrastructure.'"